We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Ramsha
Ali
ramsha.ali@manchester.ac.uk
Dr
James
Bluett
james.bluett@manchester.ac.uk
Inflammatory polyarthropathiesPapulosquamous disorders
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
“Biologic agents” are effective treatments for psoriasis and psoriatic arthritis. They are expensive, - £10,000 per patient per year. However, in about one in five patients where biologics work initially, the treatment stops working a few months later, or patients may develop a bad reaction and the drugs have to be stopped. At present, we do not know which patients are likely to fail on treatment and/or get side-effects.
The body’s immune system can react against the biologic drug by producing antibodies. A previous study, in relatively few rheumatoid arthritis patients, found that drug antibodies stopped the biologics from working and led to side-effects. We will study patients with psoriasis and psoriatic arthritis, and assess whether antibodies affect how drugs work, if prescribing other treatments such as methotrexate at the same time lowers the chances of antibody production. The ability to predict a lack of response at an early stage of treatment with a biologic, or prevent this by addition of medications such as methotrexate could ensure that these expensive drugs can be given to patients responding well in a cost-effective manner.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Clinical Laboratory Study;
You can take part if:
You may not be able to take part if:
1) Patients either unwilling or unable to donate a blood sample or subjects unable to provide informed consent or to participate in follow ups. 2) Either the individual, their General Practitioner or Consultant feels it is inappropriate for any reason for the patient to be enrolled. 3) Patients not of Northern European Caucasian decent.
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
The study is sponsored by University of Manchester and funded by Medical Research Council (MRC) .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 13910
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
